HTML
-
Chronic hepatitis B virus (HBV) infection is a worldwide health problem. HBV is an enveloped virus that contains a circular DNA genome, approximately 3.2 kb, including four overlapping open reading frames (S, C, P, and X genes), and replicates its genomic DNA through reverse transcription by the viral reverse transcriptase (Valaydon and Locarnini 2017). The hepatitis B core antigen (HBcAg) and hepatitis B surface antigen (HBsAg) are major targets for antiviral immunity, but the first one seems to be the most immunogenic (Vanlandschoot et al. 2003) and subjected to a wide variation of amino acid sequences during chronic HBV infection (Carman et al. 1995). Indeed, it is estimated that the mutation rate is 10-4–10-6 nucleotide substitutions/site/year in HBV pre-C/C gene, approximately 100 times higher than that of any other DNA virus (Girones and Miller 1989). Lack of proof-reading of the viral reverse transcriptase (Valaydon and Locarnini 2017) and host immune pressure (Wang et al. 2010) are reasoned to be the basis for the high mutation rate of HBV. However, investigative tools such as cell culture systems that support long-term HBV propagation are still lacking.
Dictated by the host immunity, the natural course of chronic HBV infection may undergo five phases: the immune tolerant phase (HBeAg-positive chronic infection), the immune-clearance phase (HBeAg-positive chronic hepatitis), the low replicative phase (HBeAg-negative chronic infection), the immune reactivation phase (HBeAgnegative chronic hepatitis), and, rarely, the recovery (HBsAg-negative phase) (EASL 2017). Patients with mother-to-infant transmission of HBV often remain in the immune tolerant phase for decades. These patients have very weak specific T cell responses, as the HBV DNA levels are high and constant, alanine transaminase (ALT) values are normal, and there is minimal liver inflammation (EASL 2017). Later they may enter into the immuneclearance phase, during which the host immunity is, for unknown reason, awakened to cause notable liver inflammation. The immune-clearance phase may then transit into the low replicative phase, during which seroconversion to positive anti-HBe sometimes occurs, HBV DNA remains at very low levels, and ALT return to normal; alternatively some patients enter into the reactivation phase with higher ALT and return of viremia.
The key to tackle HBV infection seems to lie on the interaction between the host immunity and the virus adaptation. Given the same source of infection, mother-to-infant or intrafamilial transmission of HBV provides a useful model to characterize the virus evolution pattern under different host immune background. In the present study, to shed light on the interaction between host immunity and HBV evolution, we performed longitudinal analysis of HBV pre-C/C sequences within family members infected with the same original pathogen source.
-
The subjects enrolled in this study contained two groups of individuals with ongoing HBV infection. Group one included eight pairs of relatively young mothers (aged 28–37 years) and their children (aged 5.5–6.7 years) (Hu et al. 2012). During a follow-up period of 6.0–7.2 years, these mothers' health conditions were generally well, with normal liver function and normal ultrasound B liver scanning image, and they were positive for both HBsAg and HBeAg and had constantly high HBV DNA levels. Thus, they were in HBeAg-positive chronic infection phase of infection. The longitudinal blood samples from these mothers, collected at an interval of 6.0–7.2 years (Hu et al. 2012), were kept at - 20 ℃. Their eight children received hepatitis B immunoglobulin and/or three doses of hepatitis B vaccine on a standard 0-, 1-, and 6-month schedule after birth, but they were infected with HBV; the infection was defined in three children before 3 years age (Table 1: Ⅰb, Ⅴb, and ⅩⅢb) and in five others at 5.6–6.7 years age. These children were considered be perinatally infected with HBV as a consequence of immunoprophylaxis failure. The blood samples of these children were only retained at the age of 5.5–6.7 years.
Family Patient Relation Sex Age (Years) HBsAg (IU/mL) HBeAg (S/CO) HBV DNA (IU/mL) Ⅰ Ia Mother F 30.7 128640 2299.3 1.42×108 37.0 256360 2928.0 5.50×107 Ⅰb Daughter F 5.9 70720 2055.2 1.14×108 Ⅱ Ⅱa Mother F 21.4 52890 2607.8 9.04×106 28.0 29124 2119.4 3.00×106 Ⅱb Daughter F 6.1 57550 1719.4 8.99×106 Ⅲ Ⅲa Mother F 25.5 3448 3270.6 5.91×106 32.3 8752 1885.7 5.29×106 Ⅲb Daughter F 6.4 11130 1876.5 5.97×106 Ⅳ Ⅳa Mother F 25.8 149280 2297.9 1.06×107 33.0 139260 2794.2 1.08×107 Ⅳb Son M 6.7 133200 2178.9 2.32×107 Ⅴ Ⅴa Mother F 25.6 36758 1820.9 2.39×106 32.7 94220 2612.9 3.67×107 Ⅴb Son M 6.7 31676 1662.9 4.11×107 Ⅵ Ⅵa Mother F 22.5 32580 1542.3 5.99×106 28.5 81490 1829.3 2.63×107 Ⅵb Daughter F 5.6 60600 2279.6 1.27×108 Ⅶ Ⅶa Mother F 27.4 37688 1133.0 5.68×106 34.3 60530 1510.8 1.27×107 Ⅶb Daughter F 6.5 69900 1693.3 2.14×107 Ⅷ Ⅷa Mother F 24.2 84270 1655.5 2.16×107 30.2 27038 1759.0 2.60×107 Ⅷb Son M 5.5 70942 1489.8 2.13×107 All patients were negative for IgM antibody against hepatitis B core antigen, and had normal levels of ALT. They were in the phase 1, the HBeAg-positive chronic infection phase, previously known as the immune tolerant phase of HBV infection. Table 1. Virological characteristics in group one consisting of younger mothers and their children.
Group two contained 15 individuals from six families, including six index patients (aged 40–78 years), and nine patients (aged 21–53 years) who were assumed to have acquired the infection in their early childhood from the index, except in family ⅩⅣ who were two spouses, and the husband was assumed to have acquired the infection from his wife as he was negative for HBV before he got married.
Of the above 31 patients, 20 (64.5%) were women. All the patients had no co-infection of HIV or hepatitis C virus, and had not been treated with antiviral agents. The demographic data of these patients are presented in Tables 1 and 2.
Family No. Patient No. Relation Sex Age (Years) HBsAg (IU/mL) HBeAg (S/CO) anti-HBe (S/CO) HBV DNA (IU/mL) ALT (U/L) Phasea Ⅸ Ⅸa Index F 78 92 0.4 0.2 5.51×106 969.8 2 Ⅸb Daughter F 53 1803 - + 2.40×102 12.6 3 Ⅸc Son M 45 97005 2214.9 - 1.59×108 34.5 1 X Xa Index F 71 254 - + 2.86×106 237.1 4 Xb Son M 40 168 - - 1.32×102 16.9 3 Ⅺ Ⅺa Index F 63 244.11 1.58 1.72 Undetectable 78.2 2 Ⅺb Son M 41 983 6.9 1.75 1.05×106 44.8 2 Ⅺc Son M 38 827 - + 3.28×102 17.9 3 Ⅻ Ⅻa Indexb F 46 - - + Undetectable 22.4 5 Ⅻb Daughter F 23 10182 - + 3.40×102 24.6 3 Ⅻc Son M 21 4678 490.4 16.02 1.26×106 550.3 2 ⅩⅢ ⅩⅢa Index M 46 5725 - + 1.51×102 40.3 3 ⅩⅢb Son M 22 5202 - + 1.43×102 19.5 3 ⅩⅣ ⅩⅣa Index F 40 155 0.6 + 1.94×103 71.8 2 ⅩⅣb Husband M 40 0.8 - - 1.25×102 14.7 3 All patients were positive for total antibody against hepatitis B core antigen.
aPhases 1–5 refer to HBeAg-positive chronic infection, HBeAg-positive chronic hepatitis, HBeAg-negative chronic infection, HBeAg-negative chronic hepatitis, and HBsAg-negative phase, respectively.
bThis patient had history of chronic HBV infection and did not receive antiviral therapy, but showed negative HBsAg and positive anti-HBs at the enrollment.Table 2. Virological characteristics in group two consisting of elderly parents and adult offspring.
-
Serum samples were tested for HBsAg, antibody against HBsAg (anti-HBs), HBeAg, anti-HBe, and anti-HBc using enzyme-linked immunosorbent assay kits (Huakang Biotech, Shenzhen, China). Quantification of serum HBsAg and HBeAg was performed by a microparticle enzyme immunoassay (Architect System, Abbott, North Chicago, IL, USA), as previously reported (Liu et al. 2015). HBeAg levels were presented as the ratio of relative light units of the samples to negative controls (S/CO). Quantification of HBV DNA was performed by a fluorescent real-time PCR assay (Shenyou Biotechnology, Shanghai, China) as described before (Liu et al. 2015).
-
Serum DNA was extracted from 200 μL serum by phenol/ chloroform extraction method, and dissolved in 20 μL Tris–EDTA buffer as reported previously (Xu et al. 2017). The pre-C/C regions were amplified by nested PCR using primers as listed in Supplementary Table S1. The first round PCR was carried out using primers C1 and C2. The second round was performed using C3 and C4 primers. To prevent cross contamination, each step was performed in separate areas with dedicated equipment, and always included negative controls.
The purified PCR products were directly sequenced on an ABI Prism 3730xl sequencer (Applied Biosystems, Hitachi, Tokyo, Japan) after reaction with BigDye Terminator v3.1 (Applied Biosystems, Foster, CA, USA). When mixed signals (multiple peaks) were seen in the chromatograms of sequencing results, the PCR products were subcloned using pUCm-T vector (Sangon Biotech, Shanghai, China).
HBV genotypes were determined by phylogenetic analysis as previously described (Luo et al. 2019) based on the pre-C/C sequence. Sequences were also aligned with reference stains, including one (GQ205441) isolated in nearby city Hefei in eastern China (Zhang et al. 2011), one (KR013798) in Guangzhou in southern China (Liang et al. 2015), one (KU519422) in Tibet in western China, and one (LC170476) in Japanese patients. Multiple sequence alignments were performed using Clustal W method. Phylogenetic trees were constructed using neighboringjoining methods (Saitou and Nei 1987) with pairwise distances being estimated by Kimura's two-parameter method (Kimura 1980). The evolutionary distances were computed using the maximum composite likelihood method (Tamura et al. 2004). These analyses were done automatically using MegAlign software program (Clewley and Arnold 1997).
-
Statistical analysis was performed with SPSS software (SPSS Standard v. 17.0, Chicago, IL). Unpaired t test was used to determine the significance in mutation rates between two groups with 95% confidence intervals (CI). All tests were two-sided; P < 0.05 was considered as a significant difference.
Study Population
Detection of Serological Markers for HBV Infection
HBV Genotyping and Analysis of Pre-C/C Mutations
Statistical Analysis
-
As shown in Table 1, the serum levels of HBsAg, HBeAg, and HBV DNA in each of eight mothers in group one had no significant changes during 6.0–7.2 years (from the second trimester of pregnancy to 5.5–6.7 years postpartum). The HBV DNA levels were constantly higher than 1.0 × 106 IU/mL among all eight mothers. Meanwhile, the levels of HBsAg, HBeAg, and HBV DNA in each child were also comparably high. In addition, these patients had normal ALT levels (data not shown). Thus, all patients in group one were in the HBeAg-positive chronic infection phase, also known as the immune tolerant phase according to 2017 European association for the study of the liver (EASL) guidelines (EASL 2017).
Table 2 shows the virological characteristics in patients in group two at a single time point. Of the six index patients, three were over 60 years old and three others were over 40 years old. Most of the patients were in natural phases 2–4 based on the EASL guideline (EASL 2017). Noticeably, seven patients underwent spontaneous HBeAg seroconversion, two had seroclearance of HBeAg without development of anti-HBe, and five showed coexistence of HBeAg and anti-HBe. Additionally, one index patient (Ⅻa) spontaneously cleared HBsAg and developed antiHBs with undetectable HBV DNA and normal ALT value, indicative of recovery from HBV infection, thus falling into the HBsAg-negative phase (EASL 2017).
-
Comparison of pre-C/C gene (624 bp) sequences recovered during the second trimester and 5.5–6.7 years postpartum revealed that pre-C/C gene had no mutation in seven women, and one single nucleotide substitution in one woman (ⅩⅢa) (Table 3). The sequences recovered from their children were identical to the sequences in their mothers during pregnancy. Moreover, among four reference strains (GQ205441, KR013798, KU519422, LC170476) that were isolated in China or Japan, the strain (GQ205441) in a neighboring city is evolutionarily closest to the sequences in group one (Fig. 1A). The variation rate of nucleotides between GQ205441 and the sequences in group one was only 0.48%–1.44%, and none leads to an amino acid variation (Table 3).
Family Patient Relation Sex Age (Years) Compared to indexa Compared to GQ205441 nt (%) aa (%) nt (%) aa (%) Group one Ⅰ Ⅰa Index F 30.7 - - 3 (0.48) 0 (0.0) 37.0 0 (0.0) 0 (0.0) 3 (0.48) 0 (0.0) Ⅰb Daughter F 5.9 0 (0.0) 0 (0.0) 3 (0.48) 0 (0.0) Ⅱ Ⅱa Index F 21.4 - - 5 (0.8) 0 (0.0) 28.0 0 (0.0) 0 (0.0) 5 (0.8) 0 (0.0) Ⅱb Daughter F 6.1 0 (0.0) 0 (0.0) 5 (0.8) 0 (0.0) Ⅲ Ⅲa Index F 25.5 - - 4 (0.64) 0 (0.0) 32.3 0 (0.0) 0 (0.0) 4 (0.64) 0 (0.0) Ⅲb Daughter F 6.4 0 (0.0) 0 (0.0) 4 (0.64) 0 (0.0) Ⅳ Ⅳa Index F 25.8 - - 4 (0.64) 0 (0.0) 33.0 0 (0.0) 0 (0.0) 4 (0.64) 0 (0.0) Ⅳb Son M 6.7 0 (0.0) 0 (0.0) 4 (0.64) 0 (0.0) Ⅴ Ⅴa Index F 25.6 - - 5 (0.8) 0 (0.0) 32.7 0 (0.0) 0 (0.0) 5 (0.8) 0 (0.0) Ⅴb Son M 6.7 0 (0.0) 0 (0.0) 5 (0.8) 0 (0.0) Ⅵ Ⅵa Index F 22.5 - - 8 (1.28) 0 (0.0) 28.5 0 (0.0) 0 (0.0) 8 (1.28) 0 (0.0) Ⅵb Daughter F 5.6 0 (0.0) 0 (0.0) 8 (1.28) 0 (0.0) Ⅶ Ⅶa Index F 27.4 - - 4 (0.64) 0 (0.0) 34.3 0 (0.0) 0 (0.0) 4 (0.64) 0 (0.0) Ⅶb Daughter F 6.5 0 (0.0) 0 (0.0) 4 (0.64) 0 (0.0) Ⅷ Ⅷa Index F 24.2 - - 9 (1.44) 0 (0.0) 30.2 1 (0.001) 0 (0.0) 8 (1.28) 0 (0.0) Ⅷb Son M 5.5 0 (0.0) 0 (0.0) 9 (1.44) 0 (0.0) Group two Ⅸ Ⅸa Index F 78 - - 23 (3.69) 15 (7.2) Ⅸb Daughter F 53 35 (5.61) 28 (13.46) 24 (3.85) 17 (8.2) Ⅸc Son M 45 22 (3.53) 14 (6.73) 6 (0.96) 1 (0.5) Ⅹ Ⅹa Index F 71 - - 9 (1.44) 5 (2.4) Ⅹb Son M 40 14 (2.24) 10 (4.80) 13 (2.08) 7 (3.4) Ⅺ Ⅺa Index F 63 Undetectable Ⅺb Son M 41 - - 6 (0.96) 4 (1.9) Ⅺc Son M 38 19 (3.04) 11 (5.29) 23 (3.69) 15 (7.2) Ⅻ Ⅻa Index F 46 Undetectable Ⅻb Daughter F 23 - - 14 (2.24) 10 (4.8) Ⅻc Son M 21 20 (3.21) 15 (7.21) 13 (2.08) 8 (3.8) ⅩⅢ ⅩⅢa Index M 46 - - 24 (3.85) 14 (6.7) ⅩⅢb Son M 22 27 (4.33) 19 (9.13) 7 (1.12) 7 (3.4) ⅩⅣ ⅩⅣa Index F 40 - - 15 (2.4) 10 (4.8) ⅩⅣb Husband M 40 16 (2.56) 12 (5.76) 13 (2.08) 7 (3.4) aPre-C/C sequences were compared to the sequences recovered from the index patients during the second trimester in families Ⅰ–Ⅷ, and to the sequences recovered from the index patients or other infected family members in families Ⅸ–ⅩⅣ. Table 3. Nucleotide and amino acid variations in pre-C/C gene among family members or compared to GQ205441.
Figure 1. Phylogenetic analysis of pre-C/C region of HBV. Phylogenetic tree was constructed based on the pre-C/ C sequences (624 bp) from samples in families Ⅰ–Ⅷ in group one (A) and families Ⅸ– ⅩⅣ in group two (B). The sequences GQ205441 (Heifei, China), KR013798 (Guangzhou, China), KU519422 (Tibet, China), LC170476 (Tokyo, Japan) (all genotype C) retrieved from GenBank were used as references.
-
HBV DNA were undetectable in the serum samples from two index patients in group two, presumably due to the extremely low viral load. In 13 other patients in group two, pre-C/C sequences varied significantly among the patients in each family. Compared to those in the index patients or between other family members, the nucleotide sequences and amino acid residues in pre-C/C region showed 2.24%–5.61% and 4.8%–13.46% differences respectively (Table 3), significantly higher than those observed in group one (P < 0.001). When compared to GQ205441, the nucleotide sequences and amino acid residues in patient Ⅸc, who was in phase 1, had 0.96% and 0.5% difference respectively, similar to those observed in group one; whereas the nucleotide sequences and amino acid residues in the other 12 patients had 1.12%–3.68% and 1.9%–8.2% difference respectively, significantly higher than those observed in group one (P < 0.001). Phylogenetic analysis showed highly close evolutionary relationship between each mother (both during pregnancy and at 5.5–6.7 years postpartum) and her child in all families in group one (Fig. 1A), but relatively distant relationship among members in each family in group two (Fig. 1B).
-
When compared with GQ205441, a total of 106 different point substitutions were detected in pre-C/C gene in this study. No deletions or insertions were found within pre-C/ C gene. Of them, 75 nucleotide substitutions, including six double mutations and two triple mutations, lead to 64 missense mutations and one nonsense mutation (i.c. G1896A). Sixty-one amino acid variations occurred in core protein (Fig. 2), the majority (72%) of which spread out within previously reported epitopes for T cells, cytotoxic T lymphocytes (CTLs), or B cells (Salfeld et al. 1989; Bertoletti et al. 1991, 1993; Ferrari et al. 1991; Sallberg et al. 1993; Carman et al. 1997). The other four non-synonymous mutations occurred in pre-C gene, among which the most prevalent one is the nonsense mutation G1896A, found in five HBeAg-negative patients (Ⅺc, Ⅸb, Ⅹa, Ⅹb, ⅩⅣb) and three (Ⅸa, Ⅺb, ⅩⅣa) who was undergoing seroconversion.
Status of Hepatitis B Serological Markers and HBV DNA Level
High Conservation of Pre-C/C Gene in Young Mothers and Their Children During 6.0–7.2 Years
Divergent Mutations of Pre-C/C Gene in Older Spreader and the Adult Offspring
Non-synonymous Substitutions Spread Out Immune Epitopes in Core Protein and Prevail in G1896
-
In the present study, we investigated the evolution of preC/C gene sequences in 31 patients from 14 families with known perinatal/intrafamilial HBV infection. We found that in the immune tolerant phase, pre-C/C sequences remained almost unchanged during 6.0–7.2 years in both the spreaders and the infected children, and had high homology to the sequences of HBV strain GQ205441 isolated from a nearby city (Zhang et al. 2011). By contrast, the intrafamilial transmitted HBV had gained diversified mutations in pre-C/C gene among the family members mostly in immune-clearance and low replicative phases. These results indicate that HBV pre-C/C gene is highly conservative during the immune tolerant phase, and mutations emerge around the time of the immune-clearance phase that is often coincided with decrease or loss of HBeAg. Seemingly, it may be the host immune pressure that decidedly drives the genesis of HBV mutations.
It has long been considered that the viral reverse transcriptase of HBV has an error-prone nature, and HBV thus evolves with a high mutation rate similar to that of RNA viruses (Holmes 2008). The estimated half-life of circulating HBV varies, from 2.5 to 46 min (Dandri et al. 2008) to 4–24 h (Murray et al. 2005, 2006). In the present study, HBV DNA levels in the mothers from group one during the second trimester were comparable to those at 5.5–6.7 years postpartum (Table 1). To maintain such constant circulating viral loads, the circulating HBV should be replenished at least by 50% per day based on an estimated half-life of 24 h. By simple calculation, the HBV in the paired mother–child should have noticeable mutations during the observation period of 6.0–7.2 years (Girones and Miller 1989). However, of eight women, seven did not have any substitution, and one had only one nucleotide substitution yet nonsense mutation at 6.0–7.2 years follow-up (Table 3). Moreover, the pre-C/C gene in the eight children had identical sequences to their mothers (Table 3, Fig. 1A). These results indicate that in the immune tolerant phase, even the error-prone nature of HBV replication was hardly able to introduce detectable mutation into pre-C/C gene.
Noticeably, compared with the sequence of HBV GQ205441, which was isolated in a nearby city in China, the pre-C/C sequences from individuals in immune tolerant phase (group one) had high (98.56%–99.52%) homology at nucleotide level and complete homology (100%) at amino acid level (Table 3). The patient (Ⅸc) in immune tolerant phase in group two also had high homology at nucleotide and amino acid levels with GQ205441 (Table 3). The high homology was unlikely caused by cross-contamination, as GQ205441 was isolated in a different institute, and the sequences among all the index patients were indeed diversified (Fig. 1). These findings suggest that a predominant HBV isolate is circulating in this region, and its pre-C/C gene has maintained highly conservative in immune tolerant phase even among different individuals. These results also imply that with little host immune pressure in play, proof-reading-deficient viral reverse transcriptase rarely causes detectable replication error.
On the other hand, the pre-C/C gene in the subjects who were in non-immune tolerant phases (group two) showed diversified sequences (Table 3, Fig. 1B), despite that the family members most likely acquired the same HBV sources from the index patients. Of the 15 patients, one was in the immune tolerant phase with high viral load over 1.0 × 108, and 14 others were in other phases among which 10 had significantly reduced HBV DNA levels of ~ 1.0 × 10-4 IU/mL (Table 2). Thus, it is probable that most patients in group two had developed specific immune pressure against HBV, at least during a certain period. Therefore, the pre-C/C gene mutations were likely resulted from the long-term immune pressure as reported previously (Wang et al. 2010).
The underlying mechanism that drives HBV evolution during its chronic infection has intrigued microbiologists for long (Croagh and Lubel 2014; Warner et al. 2014; Boeijen et al. 2017; Faure-Dupuy et al. 2017; Lazarevic et al. 2019). A quasi-species theory has been proposed to explain the interplay between the host immune pressure and the HBV genomic diversity (Warner et al. 2014). When there is only low immune pressure (such as in the immune tolerant phase), high viral load is maintained, whereas a low selective pressure exists that leads to only few emerging adaptive mutants. Positive selection pressure occurs (such as in the immune-clearance phase) when host immunity that curtails HBV replication forces the selection of virions that contain escape mutations in the immune epitopes they recognize. Mutations under positive selection can be identified in viral subcloning by finding a high rate of non-synonymous mutations in the genes that encode the immune epitopes. An increased frequency of positively selected mutations has been shown in the pre-C/C gene of the HBV from HBeAg-negative patients (Abbott et al. 2010). In this study, samples from 9 out of 13 patients in group two required subcloning to determine the correct sequences due to mixed trace signals in the chromatogram after direct sequencing (data not shown). For each sample, a consensus sequence was determined and used. Whereas samples from group one showed rival diversity to much less extent that only one sample needed subcloning and showed variants with only synonymous mutations in pre-C/C gene. In consistent, a previous longitudinal study spanning 4–14 years that followed-up 18 patients who were treatment naı ¨ve showed that the viral diversity may stay very low and stable for many years during immune tolerant phase, followed by an increase in the viral diversity within 0–3 years around the time of HBeAg seroconversion (Nie et al. 2012). To reveal more detailed viral mutational spectrums in patients, next generation sequencing (NGS) may be required in further in-depth analysis. Indeed, NGS technologies are able to assess the mutational frequency per site and have revolutionized the way to study diversity of viral population.
HBV is a non-cytopathic virus, and the infection itself does not damage hepatocytes. Liver damage arises from cytolytic effects of the immune system, mainly the CTLs which attempt to clear HBV by killing the infected cells (Maini et al. 2000). The magnitude of such immune response has been noted to determine the course of the infection and clinical outcomes (Boeijen et al. 2017). Vigorous immune attack against infection is evidenced by elevated ALT (which are released from injured or killed hepatocytes) with suppressed viral replication. While normal ALT and active viral replication are signs for host immunity tolerant to HBV infection. This is the rationale behind the phase classification of HBV infection. Although we did not directly examine the CTL immunity in these patients, subcloning results revealed variants in group two harboring a dozen of different amino acid changes spread out immune epitopes in the core protein, including those for CD8+ T cells, CD4+ T cells, and B cells, co-exist in the serum. Clustering mutations occurred in known immunological target regions may reflect a role of the immune response for selection. On the other hand, no conclusive evidence has so far demonstrated that the accumulation of pre-C/C mutations could influence the outcomes of liver diseases.
There are several limitations in this study. First, the blood samples in the eight children in group one were available only at 5.5–6.7 years age, leaving us impossible to observe the evolution of viral sequences in these children. However, the full sequence homology between the children and their mothers indicated that the sequences in children did not undergo mutation. Second, the samples in all individuals in group two were cross-sectional. Thus, we could not longitudinally observe the evolution of the same original HBV during the different phases of infection. Third, we cannot exclude potential mutations in regions other than pre-C/C. In fact, pre-C/C encodes HBeAg and HBcAg, two major targets for CTLs- and B cells-mediated antiviral immunity. HBV e and c antigens are prone to a wide variation of amino acid sequences during chronic HBV infection (Wang et al. 2016; Colombatto et al. 2018; Luo et al. 2019). The pre-C/C is arguably the most common site for mutations in HBV (Wang et al. 2016; Luo et al. 2019). Mutations occurred to pre-C/C should reflect how conservative or radical the virus had evolved so far. Fourth, the number of study subjects was relatively small. Nevertheless, these limitations did not taint the finding that pre-C/C is highly conservative for 6.0–7.2 years in the immune tolerant phase regardless of individuals.
In summary, HBV pre-C/C gene in perinatally HBV-infected patients is highly conservative during the immune tolerant phase irrespective of different individuals, and undergoes diversified mutations around the time of ongoing immune-clearance phase. These results indicate that the emergence of viral variants is mainly driven by the host immune pressure. Mutations occurred in pre-C/C gene may mark the switch of immune tolerant to immune reactive phase in the natural course of HBV infection.
-
We thank Ms. Zhenhua Feng (Nanjing Drum Tower Hospital, Nanjing 210008, China) for performing sequencing of HBV pre-C/C gene. This study was supported by the National Natural Science Foundation of China (81672002), the Science and Technology Department of Jiangsu Province (BK20161105), and the Jiangsu Provincial Department of Health (H201537), China.
-
YHZ designed the study and critically revised the manuscript; YL and LZ performed the experiments, analyzed data and wrote the manuscript; YD and YH followed the patients, collected and analyzed the clinical data; BX participated in the design and performed the statistical analysis. All authors read and approved the final manuscript.
-
The authors declare no conflict of interests.
-
This study was approved by the institutional review boards of Nanjing Drum Tower Hospital, essentially following the ethical guidelines of the Declaration of Helsinki. Before sample collection, written informed consent was obtained from all the patients or their guardians for which identifying information is included in this article.